Inhibikase Thera falls as risvodetinib development paused

Clinical-stage USA-based drug developer Inhibikase Therapeutics (Nasdaq: IKT) saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing results from a Phase II trial of patients with untreated Parkinson's disease.

The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50mg, 100mg, 200mg or placebo for 12 weeks. The primary endpoints of this trial were safety and tolerability and there were 15 secondary endpoints to evaluate treatment benefit.

While the drug was generally well tolerated, with adverse events comparable to placebo, it failed to demonstrate significant improvement in combined motor scores on the Movement Disorder Society Universal Parkinson’s Disease Rating Scale (MDS-UPDRS).